Malta - English - Medicines Authority

melita pharm, s.l. c/roma, 6-10, 08023 - barcelona,, spain - daptomycin - powder for solution for injection/infusion - daptomycin 350 mg - antibacterials for systemic use

Malta - English - Medicines Authority

melita pharm, s.l. c/roma, 6-10, 08023 - barcelona,, spain - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 32376 - gauze, absorbable - after gelitacel has been applied to the defect, it becomes saturated with blood swelling to form a red gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of haemorrhage. to be used as an adjunct in surgical procedures to assist in the control of capillary, venous and small arterial haemorrhage.

Singapore - English - HSA (Health Sciences Authority)

amo singapore pte. limited - ophthalmology - the elita system is an ophthalmic femtosecond laser intended to create a corneal flap in patients undergoing lasik surgery/other surgery/treatment requiring initial lamellar resection of the cornea. it is also intended for flapless refractive correction via lenticule creation and removal, which alters the curvature of the corneal surface so as to correct a patient’s refraction. it is indicated for corneal refractive lenticule removal in the reduction/elimination of myopia with and without astigmatism up to -12.00d sphere, up to -6.00d cylinder, with the sum of sphere and cylinder between -1.00d and -12.00d using minus cylinder convention. the system is indicated for patients who are 18 years of age/older, with documentation of stable manifest refraction over the past year as demonstrated by a change of ≤0.50d manifest refraction spherical equivalent (mrse). it should only be operated by, or under the direct supervision of a trained physician with certification in laser safety.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 35895 - sponge, haemostatic, absorbable - following insertion of the tampon, the sponge results in rapid haemostasis by concentrating blood platelets and coagulating factors released by surgically/trauma-induced venous or diffuse oozing haemorrhage within the gelatin matrix. the gelatin scaffold is progressively broken down locally by proteases/collagenases to amino acids and collagen peptides (common to man), and fully absorbed over a period of 2-5 days on mucosal tissue, leaving no residue or scar tissue. to control bleeding in haemorrhoidectomies, anal fistula and fissures, hysterectomies and curettage.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48170 - gelatin haemostatic agent - following application of the sponge to the surface of the defect or insertion into the surgically created void, the sponge results in rapid haemostasis by concentrating blood platelets and coagulating factors released by surgically/trauma-induced venous or diffuse oozing haemorrhage within the gelatin matrix. the shape and size of the defect determines the sponge configuration most suited to the operative site. an aid to providing haemostasis and obliterating dead space created by the extraction of teeth, root amputations and removal of cysts, tumours and impacted teeth.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48170 - gelatin haemostatic agent - following application of sponge to surface of defect or insertion into the surgically created void, the sponge results in rapid haemostasis by concentrating blood platelets and coagulating factors released by surgically/trauma-induced venous or diffuse oozing haemorrhage within the gelatin matrix. to achieve local haemostasis by tamponade effect; to support and separate tissues to prevent adhesions, e.g.keep the fascia or perichondrium in place following tympanoplasty.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48170 - gelatin haemostatic agent - following delivery of the sponge into the vessel to be occluded, the sponge results in temporary embolisation by concentrating blood platelets and coagulating factors within the gelatin matrix. the shape and size of the vessel determines the sponge configuration most suited to the operative site. to achieve temporary arterial embolisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48170 - gelatin haemostatic agent - following application of the sponge to the surface of the defect or insertion into the surgically created void, the sponge results in rapid haemostasis by concentrating blood platelets and coagulating factors released by surgically/trauma-induced venous or diffuse oozing haemorrhage within the gelatin matrix. the shape and size of the defect determines the sponge configuration most suited to the operative site. to achieve rapid haemostasis by tamponade effect.

India - English - Central Drugs Standard Control Organization

eris life - pioglitazone - tab - 15/30;mg - 10